|
|
Article: ALK-Abello and Schering-Plough Announce Agreement To Develop Tablet-Based Allergy Immunotherapy.
- Article from:
- PR Newswire
- Article date:
- October 23, 2002
CopyrightCOPYRIGHT 2002 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
ALK-Abello and Schering-Plough Corporation today announced an agreement to collaborate in conducting a clinical trial of an ALK-Abello tablet-based immunotherapy for the treatment of allergy symptoms caused by grass pollens. The agreement also contains a proviso for Schering-Plough to co-develop and co-promote the grass-pollen allergy tablet and all other non-injectable allergy products in ALK-Abello's research pipeline.
The collaboration is aimed at developing new tablet-based allergy immunotherapies that have the potential to offer both patients and physicians substantial advantages over the traditional delivery method of subcutaneous injections.
...